Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen. [electronic resource]
Producer: 20120105Description: 1117-8 p. digitalISSN:- 1873-2399
- Angiogenesis Inhibitors -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Boronic Acids -- administration & dosage
- Bortezomib
- Combined Modality Therapy
- Dexamethasone -- administration & dosage
- Drug Resistance, Neoplasm -- genetics
- Epirubicin -- administration & dosage
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Male
- Middle Aged
- Multiple Myeloma -- drug therapy
- Neoplasm Proteins -- biosynthesis
- Proteasome Endopeptidase Complex -- biosynthesis
- Pyrazines -- administration & dosage
- Thalidomide -- administration & dosage
- Up-Regulation
No physical items for this record
Publication Type: Letter; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.